TREX1 mutations, leading to the loss of its exonuclease activity, have been reported in Aicardi–Goutières syndrome (AGS) and systemic lupus erythematosus (SLE) patients [37,38,39,40]. This evidence concerns the gene TREX1 and systemic lupus erythematosus.